{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Placebo+-+Control", "query": { "condition": "Placebo - Control" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 17111, "total_pages": 1712, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Placebo+-+Control&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-23T01:01:34.836Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00221442", "title": "Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Binge Eating Disorder Associated With Obesity" ], "interventions": [ { "name": "Zonegran", "type": "DRUG" }, { "name": "sugar pill", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lindner Center of HOPE", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 60, "start_date": "2005-08", "completion_date": "2009-03", "has_results": false, "last_update_posted_date": "2011-06-22", "last_synced_at": "2026-07-23T01:01:34.836Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00221442" }, { "nct_id": "NCT03100942", "title": "Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sjogren's Syndrome" ], "interventions": [ { "name": "Lanraplenib", "type": "DRUG" }, { "name": "Filgotinib", "type": "DRUG" }, { "name": "Tirabrutinib", "type": "DRUG" }, { "name": "Lanraplenib placebo", "type": "DRUG" }, { "name": "Filgotinib placebo", "type": "DRUG" }, { "name": "Tirabrutinib placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 152, "start_date": "2017-05-01", "completion_date": "2019-10-02", "has_results": true, "last_update_posted_date": "2020-10-23", "last_synced_at": "2026-07-23T01:01:34.836Z", "location_count": 34, "location_summary": "Mesa, Arizona • Phoenix, Arizona • Covina, California + 31 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Covina", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03100942" }, { "nct_id": "NCT05686070", "title": "A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prevention of Ischemic Stroke", "Acute Non-cardioembolic Ischemic Stroke", "High-risk Transient Ischemic Attack" ], "interventions": [ { "name": "Asundexian (BAY2433334)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12327, "start_date": "2023-01-26", "completion_date": "2025-10-23", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-07-23T01:01:34.836Z", "location_count": 108, "location_summary": "Fairhope, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 87 more", "locations": [ { "city": "Fairhope", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05686070" }, { "nct_id": "NCT04673656", "title": "Dose-Response Study to Evaluate the Effect of BKR-017 on Insulin Resistance and Other Metabolic Parameters in Type 2 Diabetes Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "BKR-017", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "BioKier Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 60, "start_date": "2021-04-18", "completion_date": "2023-02-07", "has_results": false, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-07-23T01:01:34.836Z", "location_count": 3, "location_summary": "Baton Rouge, Louisiana • Durham, North Carolina • Kannapolis, North Carolina", "locations": [ { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Kannapolis", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04673656" }, { "nct_id": "NCT04562766", "title": "Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Immune Thrombocytopenia" ], "interventions": [ { "name": "Rilzabrutinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Principia Biopharma, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": null, "sex": "ALL", "summary": "10 Years and older" }, "enrollment_count": 232, "start_date": "2020-12-14", "completion_date": "2026-08-26", "has_results": true, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-07-23T01:01:34.836Z", "location_count": 17, "location_summary": "Los Angeles, California • San Francisco, California • Torrance, California + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04562766" }, { "nct_id": "NCT03046056", "title": "Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Bowel Crohn's Disease" ], "interventions": [ { "name": "Filgotinib", "type": "DRUG" }, { "name": "Placebo to match filgotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 78, "start_date": "2017-04-11", "completion_date": "2020-07-20", "has_results": true, "last_update_posted_date": "2021-08-23", "last_synced_at": "2026-07-23T01:01:34.836Z", "location_count": 15, "location_summary": "Miami, Florida • Orlando, Florida • Tampa, Florida + 12 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03046056" }, { "nct_id": "NCT01369329", "title": "A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn's Disease", "IBD", "Colitis", "Inflammatory Bowel Disease" ], "interventions": [ { "name": "Group 2 ustekinumab 130 mg", "type": "DRUG" }, { "name": "Group 3: ustekinumab approximately 6 mg/kg", "type": "DRUG" }, { "name": "Group 1: Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 769, "start_date": "2011-07", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2016-12-07", "last_synced_at": "2026-07-23T01:01:34.836Z", "location_count": 67, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 64 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Redwood City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01369329" }, { "nct_id": "NCT04202679", "title": "Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neurodermatitis" ], "interventions": [ { "name": "Dupilumab SAR231893", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Moisturizers", "type": "DRUG" }, { "name": "Low to medium potent topical corticosteroids", "type": "DRUG" }, { "name": "Topical calcineurin inhibitors", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 160, "start_date": "2020-01-16", "completion_date": "2021-11-22", "has_results": true, "last_update_posted_date": "2025-09-17", "last_synced_at": "2026-07-23T01:01:34.836Z", "location_count": 7, "location_summary": "Fort Smith, Arkansas • Sacramento, California • Pembroke Pines, Florida + 4 more", "locations": [ { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Sacramento", "state": "California" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Plainfield", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04202679" }, { "nct_id": "NCT03895996", "title": "Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "AVT001", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Avotres Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 25, "start_date": "2019-06-20", "completion_date": "2023-12-19", "has_results": true, "last_update_posted_date": "2025-03-05", "last_synced_at": "2026-07-23T01:01:34.836Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03895996" }, { "nct_id": "NCT04657003", "title": "A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes", "Overweight", "Obesity" ], "interventions": [ { "name": "Tirzepatide", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 938, "start_date": "2021-03-29", "completion_date": "2023-04-10", "has_results": true, "last_update_posted_date": "2024-04-08", "last_synced_at": "2026-07-23T01:01:34.836Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Huntington Park, California + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Huntington Park", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Montclair", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04657003" } ] }